Clinical and BIOgical Analyses of RECtal Tumors (BIOREC)
Rectal cancer is a common cancer with an incidence of approximately 14,000 new cases per year in France. The survival rate is approximately 50% at 5 years, ranging from 90% for patients with localized rectal cancer to 18% for patients with metastases.
Surgery with local or complete exicion is the standard treatment for early stages. The implementation of Total Neoadjuvant Therapy (TNT) for locally advanced stages has led to a significant improvement in the prognosis for rectal cancer. The complete pathological response rate of aproximately 20% after TNT has led to the "Watch and Wait" strategy, which aims to avoid surgery and preserve the rectum, but there is currently no reliable method for identifying responders. Rectal tumors with mismatch repair defiency (MMRd) and/or High microsatellite instability (MSI-H) are considered resistant to neoadjuvant chemotherapy, but those patients can benefit from immunotherapy treatment. Identifying patients who will respond to immunotherapy is crucial for this type of treatment. Pre-existing immune infiltration within the tumor microenvironnement prior to any treatment is an important prognostic factor and could help predict response to immunotherapy, as well as neoadjuvant treatment. Studying the immune microenvironnement and how it changes during different treatments could therefore help identify responders for whom treatment without surgery could be considered in order to avoid the deterioration in quality of life often associated with this procedure in this type of cancer. Finally, analysis of residual tumor cells after chemotherapy and/or chemoradiotherapy could help identify possible mechanisms of resistance to current treatments and develop strategies to counter them.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Philippe CASSIER, MD
- Phone Number: (+33)04 26 55 68 33
- Email: philippe.cassier@lyon.unicancer.fr
Study Contact Backup
- Name: Lucas DE CRIGNIS, MD
- Email: lucas.decrignis@lyon.unicancer.fr
Study Locations
-
-
-
Lyon, France
- Centre Léon Bérard
-
Contact:
- Lucas DE CRIGNIS, MD
- Email: lucas.decrignis@lyon.unicancer.fr
-
Contact:
- Philippe CASSIER, MD
- Phone Number: (+33)4 26 55 68 33
- Email: philippe.cassier@lyon.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged 18 or over
- Patients who have undergone surgery for rectal cancer since January 1st, 2019
- Histological diagnosis of rectal adenocarcinoma confirmed on a surgical sample
Exclusion Criteria:
- Not applicable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adult patient with rectal cancer undergoing surgery at Centre Léon Bérard from 2019
|
Blood sample will be collected during a visit scheduled as part of the standard care for the patient
A healthy tissue sample from the surgical site (excision margin) of the primary tumor or from an additionnal sample taken during preoperative rectosigmoidoscopy performed as part of the standard care will be collected.
Archival FFPE (Formalin-Fixed Paraffin-Embedded) or Fresh Frozen tumor samples from initial diagnosis, surgery, and metastases in case of relapse will be collected if available.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Establish a correlation between biological data and clinical data of patients with rectal tumors
Time Frame: Until up to 3 years follow-up of the last patient enrolled
|
Until up to 3 years follow-up of the last patient enrolled
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of stroma of tumor samples from : 1) primary tumors operated after preoperative chemotherapy, 2) biopsies performed before chemotherapy and 3) primary tumors operated without preoperative treatment
Time Frame: Until up to 3 years follow-up of the last patient enrolled
|
Until up to 3 years follow-up of the last patient enrolled
|
|
Comparision of healthy tissue, stroma of primary tumors samples and metastases in patients for whom samples of primary tumor and metastases will be available.
Time Frame: Until up to 3 years follow-up of the last patient enrolled
|
Until up to 3 years follow-up of the last patient enrolled
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET25-227
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.